

April 21, 1969

Dr. Turan Itil
Professor of Psychiatry
Missouri Institute of Psychiatry
St. Louis, Missouri

Ref: CP- 14,368

Dear Turan,

For some time I have expressed the desire to examine a novel potential psychoactive compound in the EEG analytic screen, without the usual animal or clinical clues, which could influence our EEG evaluations. Drs. Berger and Pitts of Pfizer Medical Research Laboratories have made such a study possible, and I am writing to ask your assistance.

Enclosed is a copy of the available animal and clinical pharmacology data, as supplied by Dr. Berger. I would be grateful for your review of this material and your response to the following questions, which I propose to use in formulating a definitive pilot study. As I would like to start with single, oral dosages in young (21-35 years) male volunteers, the questions are:

What dosage should be tested initially ? If no effect, what increments should be tested ?

At what time intervals can we anticipate clinical and/or EEG effects ?

What is the maximum dose that should be tested before your review of the data ?

What secondary effects should be tested for most carefully ? Assuming some secondary effects are experienced, what are the prohibited antagonists? the preferred, if known ?

What are the primary EEG leads to be examined?

Any behavioral questions that may be anticipated in addition to the ones included in the Clyde Mood Scale, which we have used in these studies to date ?

Itil 2 April 21, 1969

I would like to begin these studies about June 1, and would appreciate the opportunity to discuss this with you before the APA meetings in May.

Many thanks, and my best regards.

Sincerely yours,

Max Fink, M.D.